Healthcare
Pharmagen, Inc.(PHRX)
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 17, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pharmagen, Inc. (PHRX) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin -44.9% and ROIC 73.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.1. Stock Foundry combines PHRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-44.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near -44.9%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHRX Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PHRX and SPY.
Company Overview
Pharmagen, Inc.
Other OTC
Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. It offers plasma derivatives for treating serious medical conditions, such as cancer, hemophilia, rheumatoid arthritis, multiple scleroses, blood disorders, hepatitis, and HIV; and specialty products for treating respiratory, oncology, cardiovascular, and hormonal syndromes. The company also manufactures and distributes health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin. In addition, it sells traditional pharmaceuticals to its distribution customers, such as antibiotics, vaccines, and other oral and injectable pharmaceuticals; and specializes in the formulation of drugs. The company was formerly known as Sunpeaks Ventures, Inc. and changed its name to Pharmagen, Inc. in January 2013. Pharmagen, Inc. is based in Silver Spring, Maryland.
- Leadership
- Mackie A. Barch
- IPO Date
- Mar 8, 2012
- Employees
- 24
- Street Address
- 9337 Fraser Avenue
- Mailing
- Silver Spring, MD, 20910
- Region
- Silver Spring, MD, US
- Reporting Currency
- USD
- Investor Line
- 204-898-8160
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 1.1
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 63.3%
- Operating Margin
- -44.9%
- Net Margin
- -134.2%
- ROE
- 85.1%
- ROIC
- 73.0%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.11
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.